All In Biotech

Drug Trial Radar · NCT06529822

Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Phase 1 Clinical Trial of a Personalized Cancer Vaccine (PCV) Strategy in Patients With Solid Tumors and Molecular Residual Disease

Last checked: Nov 20, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

64

Planned (sponsor's estimate)

Start

Mar 20, 2025

Primary completion

Jan 31, 2030

Study completion Jun 30, 2034

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Natera, Inc.
First posted
Jul 31, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1 clinical trial to evaluate the safety, feasibility and immunogenicity of a personalized cancer vaccine strategy in patients with solid tumors and molecular residual disease. The hypothesis of the trial is that synthetic long peptide personalized cancer vaccines will be safe and capable of generating measurable neoantigen-specific T-cell responses enabling ctDNA clearance. The personalized cancer vaccines are composed of synthetic long peptides corresponding to prioritized cancer neoantigens and will be co-administered with poly-ICLC.

Conditions

  • Muscle-Invasive Bladder Carcinoma
  • Gastroesophageal Adenocarcinoma
  • Melanoma
  • Non-small Cell Lung Cancer

Interventions

  • Synthetic long peptide personalized cancer vaccineBiological

    Neoantigen vaccines will be provided on a patient-specific basis

  • Poly ICLCDrug

    Poly-ICLC will be supplied by Oncovir, Inc.

  • Signatera or Altera testingDevice

    Testing used to identify and prioritize neoantigens.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Safety as measured by treatment-emergent adverse events (TEAEs)Time frame: From 1st vaccine dose through 30 days following last dose of vaccine (estimated to be 13 months)
  2. Safety as measured by treatment-related adverse events (TRAEs)Time frame: From 1st vaccine dose through 30 days following last dose of vaccine (estimated to be 13 months)
  3. Safety as measured by serious adverse events (SAEs)Time frame: From 1st vaccine dose through 30 days following last dose of vaccine (estimated to be 13 months)
  4. Feasibility as measured by the success of enrolling patients with molecular residual diseaseTime frame: Through 30 months
  5. Feasibility as measured by the expected time frame for vaccine creationTime frame: Through 24 weeks
  6. Feasibility as measured by the rate of successful vaccine deliveryTime frame: Through 1st vaccine dose (estimated to be 24 weeks)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • AdventHealth

    Orlando, Florida · Not yet recruiting

  • Washington University School of Medicine

    St Louis, Missouri · Recruiting

  • Ohio State University

    Columbus, Ohio · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.